MedDataX Logo

The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis

NCT ID: NCT03340649

Last Updated: 2017-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-09

Study Completion Date

2018-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To observe the changes of plasma hepatocyte growth factor and soluble receptor s-Met levels in patients with sepsis, and to explore its clinical significance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

90 patients who diagnosed as sepsis were included in this study. Then keep blood samples from these patients in the first day, the third day, detect the hepatocyte growth factor and soluble receptor s-Met level in plasma byenzyme-linked immuno sorbent assay. Record Severity of illness and survival status of every patient within 28 days. Objective to evaluate the correlation between the level of hepatocyte growth factor and soluble receptor s-Met in plasma and the prognosis of the patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

taking peripheral blood

taking peripheral blood of no more than 3ml

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients admitted to ICU diagnosed of sepsis(sepsis3.0 criteria)
2. Patients signing informed consent

Exclusion Criteria

1. Age is less than 18 years old or more than 80 years old
2. Pregnant women
3. Patients with tumor、hepatitis、liver cirrhosis、acute myocardial infarction、chronic renal tubular nephritis、interstitial pneumonia、acute pancreatitis、systemic lupus erythenatosus、ulcerative colitis、crohn's disease、HELLP syndrome
4. Prothrombin time is extension in patients with after liver transplantation
5. Patients with chronic renal failure
6. Patients after kidney transplantation
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jingyuan,Xu

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jingyuan,Xu

Attending doctor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

yi yang, doctor

Role: PRINCIPAL_INVESTIGATOR

Zhongda Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongda Hospital

Nanjing, Jiangsu, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

chenglong liang, master

Role: CONTACT

Phone: 15261893562

Email: [email protected]

yi yang, doctor

Role: CONTACT

Phone: +8602583262550

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

chenglong liang, master

Role: primary

yi yang, doctor

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017ZDSYLL095-P01

Identifier Type: -

Identifier Source: org_study_id